After 24 h of incubation, no consistent differences were observed in the co-cultures treated with CSF from AD patients (groups Aβ+Tau and Aβ-Tau) compared to that from non-AD patients (group non-AD) and co-cultures not treated with CSF, used as a control (Control). This evidence concerns the gene MAPT and Alzheimer disease.